Research progress of peripheral blood non-coding RNA in pancreatic cancer

doi:10.3877/cma.j.issn.1674-3946.2023.02.026

Abstract

Abstract:

Pancreatic cancer is a digestive system tumor with a high degree of malignancy. With the deepening of research on non-coding RNA in pancreatic cancer，it has been found that non-coding RNA has important potential as biomarkers and therapeutic targets in the diagnosis of pancreatic cancer. The detection of peripheral blood non-coding RNA is favored by the majority of researchers because of its simplicity and non-invasive advantages. By collecting relevant studies on peripheral blood non-coding Rnas and pancreatic cancer in recent years，this paper reviews the research progress of peripheral blood non-coding Rnas in the diagnosis and treatment of pancreatic cancer from the perspectives of micrornas（mirnas），long-chain non-coding Rnas（lncrnas）and circrnas.

Key words: Pancreatic Neoplasms, Non-Coding RNA, Peripheral Blood, Biomarkers, Tumor

Zeqian Li, Shaolong Hao, Bo Zhang, Kailun Ji, Wei Han. Research progress of peripheral blood non-coding RNA in pancreatic cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 217-220.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2023.02.026

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2023/V17/I02/217

References 39

[1]	Ilic M，Ilic I. Epidemiology of pancreatic cancer［J］. World J Gastroenterol，2016，22（44）：9694-9705.
[2]	Vincent A，Herman J，Schulick R，et al. Pancreatic cancer［J］. Lancet，2011，378（9791）：607-620.
[3]	赵建国，廖泉，赵玉沛. 胰腺癌分子标志物研究进展［J/CD］. 中华普外科手术学杂志（电子版），2013，7（03）：224-226.
[4]	Huang J，Liu J，Chen-Xiao K，et al. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer［J］. Biomark Res，2016，4：20.
[5]	Chandra Gupta S，Nandan Tripathi Y. Potential of long non-coding RNAs in cancer patients：From biomarkers to therapeutic targets［J］. Int J Cancer，2017，140（9）：1955-1967.
[6]	谢雨婷，高军. 微小RNA在胰腺癌诊断中的研究进展［J］. 中华胰腺病杂志，2022，22（02）：148-152.
[7]	Schultz NA，Dehlendorff C，Jensen BV，et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer［J］. JAMA，2014，311（4）：392-404.
[8]	Chen J，Yao D，Chen W，et al. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer［J］. Int J Biol Markers，2022，37（1）：74-80.
[9]	Yang J，Xu R，Wang C，et al. Early screening and diagnosis strategies of pancreatic cancer：a comprehensive review［J］. Cancer Commun（Lond），2021，41（12）：1257-1274.
[10]	Szafranska-Schwarzbacht AE，Adai AT，Lee LS，et al. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma［J］. Expert Rev Mol Diagn，2011，11（3）：249-257.
[11]	Morimura R，Komatsu S，Ichikawa D，et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer［J］. Br J Cancer，2011，105（11）：1733-1740.
[12]	Kawaguchi T，Komatsu S，Ichikawa D，et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer［J］. Br J Cancer，2013，108（2）：361-369.
[13]	Liang L，Wei DM，Li JJ，et al. Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer：A study based on The Cancer Genome Atlas and bioinformatics investigation［J］. Mol Med Rep，2018，17（1）：939-951.
[14]	Muro K，Fuchs CS，Jang RWJ，et al. KEYNOTE-059 cohort 1：Pembrolizumab（Pembro）monotherapy in previously treated advanced gastric or gastroesophageal junction（G/GEJ）cancer in patients（Pts）with PD-L1+tumors-Asian subgroup analysis［J］. J Clinical Onc，2018，36（4）：1.
[15]	Wang P，Zhuang L，Zhang J，et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer，and miR-21 expression confers chemoresistance by targeting FasL［J］. Mol Oncol，2013，7（3）：334-345.
[16]	Gisel A，Valvano M，El Idrissi IG，et al. miRNAs for the Detection of MultiDrug Resistance：Overview and Perspectives［J］. Molecules 2014，19（5）：5611-5623.
[17]	Jung H，Ertl L，Janson C，et al. Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer［J］. Cancer Immunol Res，2016，4（11）：1123.
[18]	Lu Y，Lu J，Li X，et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell［J］. BMC Cancer，2014，14：85.
[19]	Ma C，Huang T，Ding YC，et al. microRNA-200c overexpression inhibits chemoresistance，invasion and colony formation of human pancreatic cancer stem cells［J］. Int J Clin Exp Pathol，2015，8（6）：6533-6539.
[20]	Singh S，Chitkara D，Kumar V，et al. miRNA profiling in pancreatic cancer and restoration of chemosensitivity［J］. Cancer Lett，2013，334（2）：211-220.
[21]	Mittal A，Chitkara D，Behrman SW，et al. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer［J］. Biomaterials，2014，35（25）：7077-7087.
[22]	Sicard F，Gayral M，Lulka H，et al. Targeting miR-21 for the Therapy of Pancreatic Cancer［J］. Mol Ther，2013，21（5）：986-994.
[23]	Huarte M. The emerging role of lncRNAs in cancer［J］. Nat Med，2015，21（11）：1253-1261.
[24]	Wang Y，Li Z，Zheng S，et al. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers［J］. Oncotarget，2015，6（34）：35684-35698.
[25]	Li L，Zhang GQ，Chen H，et al. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer［J］. Oncotarget，2016，7（44）：71773-71781.
[26]	Lu H，Yang D，Zhang L，et al. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-beta pathway activation［J］. Oncol Lett，2019，17（5）：4633-4639.
[27]	Liu Y，Feng W，Liu W，et al. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis［J］. J Cancer，2019，10（16）：3746-3756.
[28]	Lu H，Ye J，Zhang L，et al. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF-beta signaling［J］. Mol Med Rep，2019，20（5）：4533-4539.
[29]	Takahashi K，Ota Y，Kogure T，et al. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer［J］. Cancer Sci，2020，111（1）：98-111.
[30]	Pan S，Shen M，Zhou M，et al. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924［J］. Cell Death Dis，2019，10（12）：883.
[31]	Li Z，Zhao X，Zhou Y，et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer［J］. J Transl Med，2015，13：84.
[32]	You L，Wang H，Yang G，et al. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207［J］. Mol Oncol，2018，12（12）：2147-2164.
[33]	Gonzalez-Duarte A，Berk JL，Quan D，et al. Analysis of autonomic outcomes in APOLLO，a phase Ⅲ trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis［J］. J Neurol，2020，267（3）：703-712.
[34]	Zhen S，Li X. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research［J］. Hum Gene Ther，2019，30（1）：3-9.
[35]	Yang F，Liu DY，Guo JT，et al. Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer［J］. World J Gastroenterol，2017，23（47）：8345-8354.
[36]	Xu Y，Yao Y，Gao P，et al. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 and miR-1294［J］. Biochem Biophys Res Commun，2019，509（1）：138-142.
[37]	Hao L，Rong W，Bai L，et al. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation，apoptosis，and invasion by sponging miR-625 and miR-892b［J］. J Cell Biochem，2019，120（3）：3780-3789.
[38]	Xu C，Yu Y，Ding F. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells［J］. Oncol Rep，2018，40（1）：395-404.
[39]	Liu Y，Xia L，Dong L，et al. CircHIPK3 Promotes Gemcitabine（GEM）Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1［J］. Cancer Manag Res，2020，12：921-929.

Please choose a citation manager

Content to export